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Abstract
Undoubtedly, caspases are the major driving force for apoptosis execution and mechanisms of their
activation and inhibition have been largely unveiled. Recent progress has been made with regard to
the exact intracellular ordering of caspases, monitoring their activities in vivo and unveiling their
substrate degradomes. Moreover, non-caspase proteases seem to assist caspases in the completion of
the death execution program. Here we will consider some very recent data dealing with these
aspects. We will also provide novel insights into the mechanisms that dictate apoptotic variability
within a cell population.
Introduction and context
Caspases coordinate, in a proteolytic cascade and with
the help of other proteases, the rapid and efficient
elimination of a cell by apoptosis. They are classified into
monomeric initiator caspases (caspase-8 and -9) with
long prodomains (death effector domain [DED], and
caspase recruitment domain [CARD]), which are acti-
vated by recruitment to and dimerization on protein
platforms, and already dimerized effector caspases
(caspase-3, -6 and -7), which require for their activation
the cleavage (e.g., by initiator caspases) of an intersubu-
nit linker that binds to the dimer interface [1].
In the extrinsic signaling pathway, the recruitment
platform is the death-inducing signaling complex
(DISC) consisting of the activated death receptor, the
adapter FADD (Fas-associated protein with death
domain) and initiator caspase-8 and -10. In the intrinsic
mitochondrial pathway, the platform is the apoptosome,
a complex of the adapter Apaf-1 (apoptotic protease
activating factor 1), mitochondrially-released cyto-
chrome c and initiator caspase-9 [1]. In both cases, the
main role of caspase-8 and -9 is to cleave and activate
effector caspase-3 and -7. Caspase-6 is an effector caspase
with a limited substrate specificity whose exact role in
apoptosis remains ill-defined [2]. Caspase-2 is recruited
to another platform, the PIDDosome (PIDD is the p53-
induced protein with death domain), which is involved
in translating a danger signal, such as DNA damage,
into either a repair or death response depending
on the cellular or environmental context [3]. Similarly,
caspases-1, -4 and -5 in humans and caspase-11 in mice
are part of inflammasome platforms that assemble in
response to external, pathogenic stimuli and guide the
production and secretion of pro-inflammatory cytokines
such as interleukin (IL)-1 and IL-18 [4]. Under certain
circumstances, such as salmonella-infected macro-
phages, the antimicrobial, inflammatory response may
result in a caspase-1-mediated form of programmed cell
death, called pyroptosis [5]. Caspase-12 is an inhibitor of
caspase-1 [4], and caspase-14 is probably the only truly
non-apoptotic human caspase mediating keratinocyte
differentiation [1].
In the caspase field, three major issues are still under
scrutiny: why are three effector caspases needed? Are
non-caspase proteases important to support or even
replace caspase-mediated signaling? And why is effector
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in a clonal cell population?
Major recent advances
Redundancy, substrate specificity and amplification
loops in caspase signaling
Two recent papers reported on the caspase substrate
repertoire in apoptotic cells [6,7]. In one case, the
proteomesfromcontrolandapoptosis-stimulatedsystems
were separated on one-dimensional SDS-PAGE (sodium
dodecyl sulfate polyacrylamide gel electrophoresis) and
analyzed by liquid chromatography coupled with tandem
massspectrometry(LC-MS/MS)aftergelelution[6].Inthe
other approach a gel-free technology was used by
selectively biotinylating free protein amino termini that
are generated in apoptotic cells upon caspase-mediated
cleavages to enrich for LC-MS/MS [7]. Both groups
identified hundreds of new substrates and support the
concept that most of them are cleaved into domain-
containingfragmentsthatmayeithergainorlosefunction.
The cleaved substrates are often stable, suggesting that
dismantling the apoptotic cell is more like folding a tent
after carefulremoval ofpegs thandisposing debris after an
explosion. Walsh et al. [8] tested some of these substrates
for caspase-3 or -7 specificity. They found that caspase-3
was more promiscuous than caspase-7 because 12 out of
20 substrates were preferentially cleaved by caspase-3
whereas only one was more susceptible to processing by
caspase-7. Thus, caspase-3 and -7 may, in part, be
functionally distinct, explaining why caspase-3 and
caspase-7 null mice show distinct phenotypes on some
genetic backgrounds [9]. In this regard, a recent study
published for the first time a non-redundant role of
caspase-7 in mediating lipopolysaccharide-induced lym-
phocyte apoptosis and mortality in mice [10]. This might
be due to the fact that caspase-7, unlike caspase-3, can be
processed and activated by caspase-1 [11]. Thus, under
certain conditions caspase-7 may be crucial for inflamma-
tory events triggered by the caspase-1 inflammasome.
Caspase-3 can also process other caspases, such as
caspase-6 and -2. In turn, caspase-6 processes caspase-8
and -10 [2,12]. Using a specific inhibitor of caspase-3,
and small interfering RNA-mediated ablation of specific
caspases, Inoue et al. [13] recently validated this caspase
ordering pathway not only for caspase-3 but also for
caspase-7. This positions caspase-6 in an important
amplification loop downstream of caspase-3 and -7.
The role of caspase-2 in this loop still remains to be
determined. Caspase-2 was previously suggested to
function as an initiator caspase for DNA damage and
heat-shock-induced apoptosis upstream of mitochon-
dria. Meanwhile, this has been largely questioned [3]. It
seems that caspase-2 may amplify apoptotic responses
by being activated downstream of caspase-9/-3 [14] or,
alternatively, to drive a DNA damage response that
bypasses p53, B-cell lymphoma protein-2 (Bcl-2) and
caspase-3 [15]. Moreover, a non-apoptotic role of
caspase-2 was proposed in the context of DNA
damage-associated cell cycle arrest through the recruit-
ment and activation on a cytosolic and a nuclear
PIDDosome platform [3,16] because caspase-2 deficient
cells failed to show G2/M arrest, leading to more mitotic
cells whose DNA was not repaired. In accordance with
such a mechanism, Ho et al. [17] recently suggested a
tumor-suppressive role of caspase-2 by controlling cell
cycle checkpoints.
Monitoring caspases in vivo and ways to activate
them therapeutically
Since thenumberoftherapiesassociatedwithincreasedor
decreased apoptosis continue to grow, it is crucial to
directlyvisualizeandquantifyapoptosisinvivo.Edg i ng to n
et al. [18] developed fluorescently-labeled activity-based
probes (ABPs) against caspases that provided direct
readouts of kinetics of apoptosis in thymi and tumors in
live mice. In contrast to the already-used polymer-based
quenched fluorescent substrates that are cleaved in multi-
plelocationstoproducefluorescentproducts,theABPsare
retained at the site of proteolysis by forming a covalent
bond with the active-site cysteine of caspases [19]. Thus,
thefluorescentABPsshowmorerapidandselectiveuptake
into tumors and brighter signals compared to substrate
probes.
Human diseases characterized by high apoptosis resis-
tance, such as cancer, may be treated in the future with
small-molecule drugs that can activate effector caspase
proenzymes. Wolan et al. [20] used high-throughput
screening to identify a compound that promoted
selective autoproteolytic activation of pro-caspase-3 at
physiological concentrations by stabilizing the on-state
conformation of the proenzyme. Moreover, Walters et al.
[21] recently reported on a caspase-3 mutation that
prevented the intersubunit linker from binding in the
dimer interface, allowing the active site to form in the
procaspase in the absence of proteolysis. This pseudo-
activated caspase-3 was not inhibited by XIAP (X-linked
inhibitor of apoptosis protein) and rapidly killed cells at
low concentrations.
With a little help from your friends: non-caspase
proteases assisting in cell death
In mammalian cells, cell death often continues when
caspases are inhibited or deleted. This form of cell death
seems to be mediated by other proteases, such as
calpains, serine proteases or lysosomal proteases,
which act in parallel with caspases to amplify apoptosis
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Calpains mainly play a pro-death role when calcium
signaling is involved. In 2005, Nicotera’s group showed
that the plasma membrane Na
+/Ca
2+ exchanger is
cleaved by calpain in the ischemic brain and in cerebellar
granule neurons exposed to glutamate leading to a Ca
2+-
mediated neuronal demise [23]. Moreover, calpains were
recently shown to redistribute to the nuclear envelope,
where they degraded nuclear pore complexes and
increased nuclear leakiness in response to a Ca
2+
overload [24]. Furthermore, calpain-1 was found to be
activated in spontaneous and Fas-mediated apoptosis
of neutrophils by a caspase-induced cleavage of its
inhibitor calpastatin. This resulted in the truncation of
pro-apoptotic Bax (Bcl-2-associated X protein) [25] and
the autophagy-related 5 (Atg5) protein [26], which both
enhanced cytochrome c release and most likely deviated
the cells from autophagy to apoptosis.
Masson and Tschopp [27] identified a family of serine
proteases, the granzymes (Gzms), present in cytotoxic
T cells and natural killer cells, which were capable of
eliminating virally infected and malignant cells in
cooperation with the FasL-Fas signaling system.
Meanwhile, it has become clear that GzmB mediates
caspase-dependent apoptosis by either cleaving Bid
(BH3-interacting domain death agonist) and activating
Bax/Bak-dependent cytochrome c release or directly
processing caspase-3 [28]. By contrast, Metkar et al.
[29] recently reported that GzmA contributes to anti-viral
immunity, not via its pro-apoptotic action, but by
triggering the processing of pro-IL-1b to mature IL-1b,
thereby stimulating a pro-inflammatory response. Thus,
Gzms resemble caspases in their capacity to influence
both apoptosis and inflammation depending on the
isoform. In this respect, the orphan human GzmM and
GzmK may similarly act as pro-inflammatory proteases,
explaining the observed ongoing anti-viral defence in
gzmAxB-/- mice [30,31]. Moreover, it is conceivable that
other cell types may also exploit a serine protease-based
mechanism to regulate apoptosis. A few candidate serine
proteases have so far been proposed, such as HtrA2
(high-temperature-regulated A2), AP24 (24 kDa apop-
totic protease) and serine proteases implicated in
endoplasmatic reticulum stress-induced apoptosis [22].
Cathepsins encompass three classes of lysosomal pro-
teases, the serine proteases cathepsin A and cathepsin G,
the aspartic proteases cathepsin D and cathepsin E and
the 11 so far known human cysteine proteases, cathe-
psins B, C, F, H, K, L, O, S, V, W and X/Z [22]. They have
been implicated in apoptosis regulation because of their
cytoplasmic release due to increased lysosomal mem-
brane permeabilization (LMP) [32]. Although they
depend on acidic pH for optimal activity, they seem
to retain some of their catalytic activity at physiological
pH. Therefore, upon their release into the cytoplasm they
can directly cleave caspases [22] or, as recently reported,
pro- and anti-apoptotic members of the Bcl-2 family or
XIAP [33]. Unfortunately, in most studies, LMP was
artificially induced by lysosomotropic agents such as
Leu-Leu-OMe (L-leucyl-L-leucine methyl ester), and it
has therefore remained unclear if cathepsin release
indeed plays an initiating role in apoptosis signaling.
Now, Oberle et al. [34] report that cells deficient in
Bax/Bak, apoptosomal components or caspase-3/-7 are
resistant to LMP in response to various apoptotic stimuli,
indicating that cathepsin release and action occurs
downstream of mitochondria. Moreover, since some
cathepsin knock-out cells (B, L but not D) exhibited
delayed but not blocked apoptosis, this lysosomal
signaling pathway seems to amplify rather than initiate
apoptosis. This process could nevertheless be physiolo-
gically relevant because a lack of this amplifcation loop
would lead to delayed cell death and/or inefficent
removal of apoptotic bodies and may be the underlying
cause of a lack of resolution of inflammation due to
neutrophilaccumulationin cathepsin Dknock-outs [35],
reduced keratinocyte apoptosis resulting in periodic hair
lossincathepsinL-deficientmice[36,37]anddiminished
liver damage upon tumor necrosis factor (TNF)-alpha
challenge in mice deficient of cathepsin B [38]. More
recently, Kirkegaard et al. [39] offered a possibility to
stabilize lysosomes by delivering Hsp70 (heat-shock
protein 70) via the endocytotic pathway. Through its
interaction with an endolysosomal phospholipid, Hsp70
facilitates the activity of acid spingomyelinase and
thereby stabilizes the lysosomal membrane. This could
be exploited to correct Niemann-Pick disease-associated
pathology (in which acid spingomyelinase is defective).
Conversely, as tumor cells express high levels of
lysosomal Hsp70, a reduction of this protein may
sensitize these cells to LMP and cathepsin-mediated cell
death.
Together with you I die: the molecular basis for
synchronous dying
It has remained enigmatic why cells, even in clonal
populations, undergo apoptosis at different rates despite
simultaneousadditionofanapoptoticstimulus.Although
caspase-3 activation occurs within minutes after cyto-
chrome c release, the duration of events preceding
cytochrome c release can vary from 1 to 24 hours. A
number of factors could contribute to this population
variability, including differences in cell cycle stages,
metabolic rates, the local environment of single cells or
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totic stimuli. Now, two recent papers reveal that the cell-
cell variability of apoptosis times is due to the divergence
of the molecular composition of the cells. Using a novel
single fluorophore reporter to measure caspase-3/-7
activities inside cells, Bhola et al. [40] report that the
onset of proteolytic activity is tightly synchronized
amongst the most related sister cells and lost over
successive generations. Similiarly, Spencer et al. [41]
found that variability in the apoptotic phenotype arises
from cell-to-cell differences in protein levels of caspases,
caspase inhibitors, Bcl-2 family members, and so on, that
exist before TRAIL (TNF-related apoptosis-inducing
ligand) exposure. A particular protein state of a single
cell is then transmitted to the daughter cells, giving rise to
transient non-genetic heritability in cell fate. Due to
ongoing protein synthesis, the protein content of sister
cells rapidly diverges so that soon these cells are no more
similar to each other than pairs of cells chosen at random.
Future directions
Although we have learned much about the regulation of
mammalian caspases, their ordering within signaling
cascades and their specific roles in particular cell death
regimens in vitro and in vivo, we do not know yet the full
scope of action of the two effector caspases-7 and -6. Is
caspase-7 mainly a downstream target of caspase-1
involved in inflammation? Is caspase-6 only an amplifier
caspase or does it play a discrete role under particular
stress responses? What about the large number of caspase
substrates that have recently been identified by mass
spectrometry [6,7]? Can they be validated in vivo (i.e.,
at physiologically relevant caspase concentrations of
1 nM in dying cells) and which of them, if any, exert a
functional significance in mediating the execution of
apoptosis? Another major task will be to determine
if caspase-2 is only a checkpoint controller, or also an
apoptoticcaspaseatspecific cellcyclestages, forexample,
leading to mitotic catastrophe, a form of apoptosis that
may depend on the molecular profile of the cell [42].
In this respect it will be exciting to continue the recent
work on determining how the protein content of
apoptosis signaling molecules sets the threshold for
death induction in single cells, preferentially supported
by systems biology approaches as shown by Spencer et al.
[41]. This will have major implications for future anti-
cancer therapies as resistance to chemotherapy is most
likely due to such cell-to-cell variability within a given
tumor cell population.
Another crucial aspect will certainly be the better
detection of apoptotic cells in diseased tissues using
specific fluorescent probes and the development of
more drugs that activate the caspase-3 proenzyme. In
particular, a drug mimicking the caspase-3 mutant
described by Walters et al. [21] holds great promise to
activate caspase-3 without proteolytic processing and
eventually to kill even tumor cells expressing high XIAP
levels.
Finally, we desperately need to understand the exact role
of non-caspase proteases in cell death regulation. The
implication of calpains, serine proteases, cathepsins and
other proteases in this process seems to be a relatively
recent evolutionary response to the complexity of
biological processes in humans. Thus, these enzymes
will be promising targets for future therapeutic interven-
tion – for example, to save neuronsor immune cells from
degeneration – irrespective of whether these proteases
amplify caspase-dependent signaling or trigger alterna-
tive caspase-independent processes. Our future work will
include the identification and molecular characterization
of more apoptotic and pro-inflammatory serine pro-
teases and the discovery of the signaling pathway leading
from caspases to LMP and cathepsin release from
lysosomes.
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